enGene Therapeutics Inc.
For the period ended Jan 31, 2025. Filed Mar 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jan 31, 2025 · Filed Mar 10, 2025
ENGN$1.75+4.2%Stored close · as of Nov 6, 2026
What changed in Risk Factors?
Read the current filingComparison unavailable
The extracted section boundaries could not be preserved reliably for this comparison. Open the source filing to review the Item.
Earlier comparable report: 10-Q, period ended 2024-07-31, filed 2024-09-10. Read that report
Unavailable is not the same as unchanged.